Tonello Stelvio, D'Onghia Davide, Di Ruscio Annalisa, Mora Silvia Maria, Vincenzi Federica, Caria Giulia, Fracchia Alessia, Vercellino Nicole, Bussolati Benedetta, Tanzi Adele, Rizzi Manuela, Minisini Rosalba, Sola Daniele, Scacchi Massimo, Mai Stefania, Pirisi Mario, Smirne Carlo, Grossini Elena, Cantaluppi Vincenzo, Comi Cristoforo, Murdaca Giuseppe, Colangelo Donato, Sainaghi Pier Paolo
Department on Translational Medicine, Università del Piemonte Orientale, 28100 Novara, Italy.
Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Pharmaceuticals (Basel). 2025 Feb 14;18(2):259. doi: 10.3390/ph18020259.
Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are severe complications of patients with systemic sclerosis (SSc). Currently, there are a few tests for early identification of these conditions, although they are invasive and time-consuming. Extracellular vesicles (EVs) offer a promising possibility for gathering information on tissue health. This study aims to characterize EVs in cases of systemic sclerosis complicated by pulmonary hypertension and pulmonary fibrosis. A cohort of 58 patients with SSc was evaluated, including 14 with pulmonary hypertension, 17 with pulmonary fibrosis, and 27 without complications. Additionally, 11 healthy subjects, matched for sex and age, served as a control group. EVs were characterized by using a MACSplex kit to analyze the expression of 37 membrane markers. After the overall analysis, we show that EVs from SSc patients had higher expression of CD146, CD42a, and CD29 ( = 0.03, = 0.02 and = 0.05) but lower expression of HLA-ABC with respect to the control patients ( = 0.02). Multivariate analyses demonstrated that only CD42a has a significant association with the disease ( = 0.0478). In group comparative analyses (PAH, ILD, uncomplicated systemic sclerosis (named SSc no PAH no ILD), and controls), CD3 and CD56 were higher in PAH patients, with respect to the controls, ILD, and the group SSc no PAH no ILD (CD3: = 0.01, = 0.003, = 0.0005; CD56: = 0.002, < 0.0001, = 0.0002). HLA-DR showed higher expression in PAH patients with respect to ILD patients ( = 0.02), CD25 showed higher expression in PAH patients with respect uncomplicated SSc ( = 0.02), and CD42a showed higher expression in PAH patients with respect to the controls ( = 0.03); nevertheless, multivariate analyses demonstrated that only CD3 retained its association with PAH. The expression of CD42a, a platelet-derived marker indicating endothelial damage, suggests its potential to provide information on the state of the microcirculation in systemic sclerosis. The higher expression of CD3 on the surface of the EVs in PAH patients might indicate increased T-cell activity in tissues, with a possible association with the development of pulmonary hypertension.
肺动脉高压(PAH)和间质性肺疾病(ILD)是系统性硬化症(SSc)患者的严重并发症。目前,虽然有一些用于早期识别这些病症的检测方法,但它们具有侵入性且耗时。细胞外囊泡(EVs)为收集有关组织健康的信息提供了一个有前景的可能性。本研究旨在对合并肺动脉高压和肺纤维化的系统性硬化症病例中的EVs进行表征。对58例SSc患者进行了评估,包括14例患有肺动脉高压的患者、17例患有肺纤维化的患者和27例无并发症的患者。此外,11名年龄和性别匹配的健康受试者作为对照组。使用MACSplex试剂盒通过分析37种膜标志物的表达来表征EVs。经过全面分析,我们发现与对照患者相比,SSc患者的EVs中CD146、CD42a和CD29的表达较高(P = 0.03、P = 0.02和P = 0.05),但HLA - ABC的表达较低(P = 0.02)。多变量分析表明,只有CD42a与该疾病有显著关联(P = 0.0478)。在组间比较分析(PAH、ILD、无并发症的系统性硬化症(称为无PAH无ILD的SSc)和对照组)中,与对照组、ILD组和无PAH无ILD的SSc组相比,PAH患者的EVs表面CD3和CD56更高(CD3:P = 0.01、P = 0.003、P = 0.0005;CD56:P = 0.002、P < 0.0001、P = 0.0002)。与ILD患者相比,PAH患者的HLA - DR表达更高(P = 0.02),与无并发症的SSc患者相比,PAH患者的CD25表达更高(P = 0.02),与对照组相比,PAH患者的CD42a表达更高(P = 0.03);然而,多变量分析表明只有CD3与PAH仍有关联。CD42a是一种表明内皮损伤的血小板衍生标志物,其表达提示它有可能提供有关系统性硬化症微循环状态的信息。PAH患者的EVs表面CD3表达较高可能表明组织中T细胞活性增加,这可能与肺动脉高压的发生有关。